Evaluating the Impact of Roche Cobas Eplex Blood Culture Panels on Diagnosing and Treating Bloodstream Infections

What this Trial Is About

This research aims to improve the diagnosis and clinical management of bloodstream infections BSIs across patients of all ages and genders who have positive blood cultures. The study evaluates the impact of rapid molecular testing using the cobasae eplex blood culture panels compared to standard culture methods. The goal is to see how quickly the most effective antibiotic treatment can be started and how this affects patient outcomes such as hospital stay length and mortality. Participants with positive blood cultures are divided into two groups. The intervention group receives testing with the cobasae eplex multiplex PCR in addition to conventional culture methods, while the control group uses only standard culture methods. The eplex system uses three panels to detect 56 organisms and 10 antibiotic resistance genes rapidly, providing results within hours. This study assesses the performance, user-friendliness, and turnaround times of the eplex compared to traditional methods. Throughout the study, researchers will monitor the time from hospital admission to the start of effective antibiotic treatment, length of hospital and ICU stays, antibiotic use intensity, and patient outcomes such as 30-day mortality and readmission rates. The study involves collecting blood culture samples, performing microbiological tests, and tracking treatment changes and patient health for up to 30 days after discharge. The overall aim is to understand if rapid molecular testing improves care for patients with bloodstream infections.

The Clinical Impact of Cobas® Eplex Blood Culture Panels for the Diagnosis of Bacteremia and Fungemia